Exhibit 99.1
Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB December
2023
Forward-Looking Statements This communication contains forward-looking
statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the
“Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s
management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and
include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking
statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as
a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s
current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that
raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of
business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the
planned clinical trials for PDS0101 and other Versamune® and Infectimune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations,
including any collaboration studies concerning PDS0101 and other Versamune® and Infectimune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results
are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including
statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently
projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily
indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical
development programs and any collaboration studies; to aid in the development of the Versamune® platform; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The
foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the
risk factors included in the Company’s annual, quarterly and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company
undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Versamune® and Infectimune® are registered
trademarks of PDS Biotechnology Corporation KEYTRUDA® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
PDS0101 to enter Phase 3 registrational trial in Q1 2024 to treat recurrent or
metastatic, HPV16-positive head and neck squamous cell cancer (HNSCC) Fast Track Designation PDS0101 addresses large and growing market with significant unmet need Transformational data generated with PDS0101 and PDS01ADC in multiple Phase
2 clinical studies Financial: Cash as of September 30, 2023 - $54.3M - Adequate cash runway into Q3 2024 with initiation of a registrational trial in 2024 Executive Summary: Positioned for Market Leadership Company Overview T cell
activating platforms and antibody conjugated immunocytokine platform to develop safer, more effective and longer-lasting cancer immunotherapies 1 2 3 4
Experienced Management Team Historical success in development and
commercialization of leading pharmaceutical products Frank Bedu-Addo, PhD Chief Executive Officer Senior executive experience with management of strategy and execution at both large pharma and biotechs Notable drug development: Abelcet®
(Liposome Company/ Elan) PEG-Intron® (Schering-Plough/ Merck) Lars Boesgaard Chief Financial Officer 20 years of financial leadership roles in healthcare Former Chief Financial Officer of publicly traded healthcare and biotech
companies Lauren V. Wood, MD Chief Medical Officer 30 years of translational clinical research experience Former Vaccine Branch Clinical Director at National Cancer Institute Center for Cancer Research Gregory Conn, PhD Chief Scientific
Officer Co-founder 35 years of drug development experience In-depth experience with biotech drug discovery, product development and manufacturing
Proprietary Investigational Drug AssetsFocused on Targeting the Immune Response
to the Tumor Water-insoluble Fatty acids/hydrocarbon chains Immunologically active R-enantiomer of 1,2-dioleoyl-trimethyl-ammonium-propane (R-DOTAP) Water-soluble and positively charged head-group coats the particle surface References:
Gandhapudi SK, et al. 2019. J. for ImmunoTherapy of Cancer 8:e000612 Greiner.JW et al ImmunoTargets and Therapy 2021:10 155–169 Versamune® T Cell Activating Platform IL-12 Fused Antibody Drug Conjugate (ADC)PDS01ADC (NHS-IL12) NHS76
(DNA-binding Ab) IL-12 (p40 clipping-resistant) De-immunized junction
Profile of PDS01ADCIL-12 fused antibody drug conjugate (tumor
targeted) PDS01ADC (M9241, NHS-IL12) immunocytokine is administered by subcutaneous injection Recombinant fusion protein consisting of the human monoclonal IgG1 antibody NHS76 fused to two molecules of the human IL-12 heterodimer at each
CH3 C-terminus NHS76 is a second-generation tumor necrosis-targeting (TNT) antibody that has been clinically validated for its ability to target lung tumors following systemic administration NHS76 targets exposed DNA/histone sites, and as a
result directs the proinflammatory cytokine IL-12 to intra-tumoral necrotic regions PDS01ADC tumor accumulation demonstrated to increase when combined with tumor necrosis-inducing agents e.g., HDAC inhibitors, chemotherapy,
radiation Safety: Evaluated in >250 subjects: Antibody modification improves safety and therapeutic profile of IL-12. Well tolerated at all doses as monotherapy, dual combination with SOC (chemotherapy, radiation etc.), and as a triple
combination with ICI and PDS0101 References: Toney NJ et al, International Immunopharmacology 116 (2023) 109736 Greiner.JW et al ImmunoTargets and Therapy 2021:10 155–169
Profile of Versamune® Designed to direct powerful CD4 (helper) and CD8 (killer)
T cells into tumors PLATFORM: Induces powerful, long-lasting anti-tumor response by promoting uptake of tumor-specific proteins by the immune system and activates a specific signaling pathway that promotes the production of active
tumor-infiltrating multifunctional CD8 killer and CD4 helper T cells Versamune® PDS0101 (HPV16) HPV+ Cancers PDS0102 (TARP) Prostate, Breast, AML PDS0103 (MUC1) NSCLC, Colon, Gallbladder, etc. PDS0104 Melanoma Product Candidates
Versamune® Induces the Right Type, Potency and Quantity of Multifunctional
Killer and Helper T Cells Comprised of positively charged lipid (R-DOTAP) co-administered with proprietary tumor-specific proteins, delivered via subcutaneous injection Presents antigen to CD4 and CD8 T cells. Activates the Type I
Interferon pathway, leading to potent, multifunctional, antigen specific T cell responses Human clinical trials confirm induction and accumulation of multifunctional T cells in the tumor, which correlated with clinical response and
elimination of circulating tumor DNA and clinical response (SITC 2022) Recruits T cells to lymph nodes Trains T cells to target tumors Arms T cells to kill tumor cells 1 2 3 Injection Site Lymph Node Tumor Site References:
Gandhapudi SK, et al. 2019. J Immunol. 202 (12): 3524-3536. Smalley Rumfield C et al. 2020J. for ImmunoTherapy of Cancer 8:e000612.
IMMUNOCERV: PDS0101 Appears to Induce Clinically Beneficial Killer (CD8) T
Cells PDS0101 activates the immune system to generate active killer T cells (CD8 T) cells that induce a critical mediator of the T cell’s tumor-killing function called granzyme-B Multifunctional killer T cells target, infiltrate and
eliminate the cervical cancer tumors 91.7% clearance of HPV16 ctDNA at week 5 vs 53.1% clearance with chemoradiation alone Quantity of tumor cell DNA circulating in the blood Killer T cells that infiltrated the tumors Representative
Subject IMMUNOCERV (PDS0101+Chemoradiation) Trial1,2: Predominantly stage III and IV cervical cancer Locally advanced cancer with tumors > 5cm (high-risk) 100% of patients had cancer spread to lymph nodes SITC 2022 100% (9/9)
clinical response rate with 60 days No evidence of cancer in 89% (8/9) by Day 170 Induction of activated CD8 T cells correlates with elimination of circulating tumor DNA1,2 1Yoshida-Court et al,, IMMUNOCERV, an ongoing Phase II trial
combining PDS0101, an HPV-specific T cell immunotherapy, with chemotherapy and radiation for treatment of locally advanced cervical cancers (NCT04580771); SITC 2022 2ASTRO 2023
HPV16-Positive Head and Neck Squamous Cell Cancer (HNSCC) Disease Overview and
Market Size
Est. HPV16Locally Advanced,Unresectable andMetastatic HPV16-Positive HNSCC
Presents a Significant Market Opportunity Largely Attributed to the High Rate of Oral HPV Infections in Men Data sources: 1 PD-L1 negative and PD-L1 positive populations (> 9000 incidence PD-L1
Positive) https://seer.cancer.gov/statfacts/html/oralcav.html; https://www.cdc.gov/cancer/hpv/basic_info/hpv_oropharyngeal.htm; https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01688-9;
https://seer.cancer.gov/statistics-network/explorer/application.html?site=3&data_type=1&graph_type=4&compareBy=sex&chk_sex_1=1&race=1&age_range=1&advopt_precision=1&hdn_view=0;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002133/ ~18,300 ~34,000 ~38,100 ~54,400 Est. U.S. HPV Positive Oral and Pharyngeal Cancer Est. U.S. Oral and Pharyngeal Cancer Est. HPV16 Genotype $2-3B Market Opportunity in US1 HPV
cancer incidences continue to increase despite preventive HPV vaccine HPV vaccination is not expected to impact the rate of HPV-positive cancer incidence for the near term Existing immunotherapies cost $150,000+ annually per patient1 No
available HPV specific therapy Initial commercial opportunity for PDS0101
Targeted treatment option to address the growing population of HPV16-positive
HNSCC and improve outcomes Novel MOA that is clinically effective in a broader patient population and provides more durable responses Safer and more effective treatments that may be used with or in place of current standard of care
Better tolerability and less toxic alternatives to chemotherapy Significant Unmet Needs Remain in Recurrent or Metastatic HNSCC KEYTRUDA® KEYTRUDA® Plus Chemo Chemotherapy + EGFR Inhibitor Objective Response Rate
(ORR) 19% 36% 35% Progression Free Survival (PFS) 3.2 mos 5.0 mos 5.0 mos 12-Month Survival Rate 50% 55% 44% Median Overall Survival (OS) 12.3 mos 13.6 mos 10.3 mos Key Toxicities Anemia Fatigue Weight
loss Hypokalemia Additional to KEYTRUDA®: Neutropenia Mucosal inflammation Thrombocytopenia Stomatitis Neutropenia Anemia Thrombocytopenia Nausea/vomiting Hypokalemia Rash Fatigue Mucosal inflammation Treatment Related
Grade 3+ Toxicities 17% 72% 69% Oncologist2 – Stated Unmet Medical Needs in HNSCC Standard of Care for Recurrent or Metastatic HNSCC – Published Results*1 1KEYNOTE-048 Study Burtness B et al, Lancet 2019 2Primary Market Research
2022 * No control or comparative studies have been conducted between immune checkpoint inhibitors and PDS0101
PDS0101 for HPV16-Positive HNSCC Phase 2 Clinical Studies
VERSATILE-002 Phase 2 Clinical Trial – Results Support Initiation of Phase 3
Clinical Trial in ICI Naïve R/M HNSCC Objective: To assess the combination of PDS0101 and KEYTRUDA® in ICI naïve subjects with recurrent or metastatic HPV-positive HNSCC KEYTRUDA® (pembrolizumab) FDA Approved Standard of
Care Partner Study Design Open-label, non-randomized, adaptive design study N=54 Enrollment complete Key Entry Criteria for ICI Naïve Subjects Recurrent or metastatic HNSCC ≥18 years of age HPV16-Positive tumor Combined positive
score (CPS) ≥1 Pembrolizumab 200mg IV Q3W up to 35 Cycles (2 years) PDS0101 1 mL subcutaneous injection at Cycles 1, 2, 3, 4 and 12 Study Treatment Primary: Best overall response (BOR) of confirmed complete response (CR) or confirmed
partial response (PR) per RECIST 1.1 Key Secondary: Progression Free Survival (PFS) per RECIST 1.1 Overall Survival (OS) Safety and tolerability Achievement of Statistical Threshold for Efficacy Endpoints Fast TrackDesignation R/M =
recurrent and metastatic
Disease Stabilization or Tumor Reduction in 81% of Patients Tumor Shrinkage in
60% (31/52) with Confirmed Objective Response in 27%1 (14/52) to Date No controlled or comparative studies have been conducted between checkpoint inhibitors and PDS0101 Assessments based on Investigator assessment per RECIST 1.1 Data on
File. 08/02/23 Data Cut. Burtness B et al., Lancet. 2019; 394:1915-1928. Best Percentage Change from Baseline in Target Lesions (mITT population) VERSATILE-002 Months (95% CI) PDS0101+KEYTRUDA® 8.1 KEYNOTE-048 (CPS≥1) Months (95%
CI) KEYTRUDA® Monotherapy 3.2 KEYTRUDA® + Chemo 5.0 EXTREME Chemo 5.0 Progression Free Survival 1Achievement of Statistical Threshold for Efficacy
PDS0101 and KEYTRUDA® Combination in ICI Naïve HNSCC Demonstrates Promising
Patient Survival to Date Median OS Not Yet Estimable Data on File. 08/02/23 Data Cut. Kaplan-Meier Estimates of Overall Survival (OS) (Intent-to-Treat Population) No. of Subjects at Risk (Events) 55 (0) 53 (2) 50 (3) 42 (5) 41
(6) 36 (7) 32 (8) 27 (8) 24 (8) 21 (8) 19 (9) 17 (9) 17 (9) 17 (9) 15 (9) 14 (9) 11 (10) 11 (10) 11 (10) 9 (10) 8 (10) 7 (10) 6 (10) 4 (10) 2 (10) 0 (10) 12 Month OS Rate – 80% 24 Month OS Rate – 74% 12-month OS
Rates CPS 1-19 = 75% CPS ≥ 20 = 85% 24-month OS Rates CPS 1-19 = Not yet estimable CPS ≥ 20 = 85%
PDS0101 and KEYTRUDA® Combination in ICI NaïveHNSCC Demonstrates Promising
Patient Survival to Date Overall Survival is Primary Endpoint in Planned Phase 3 Study VERSATILE-003 * No controlled or comparative studies have been conducted between checkpoint inhibitors and PDS0101Data on File. 08/02/23 Data CutBurtness
B et al., Lancet. 2019; 394:1915-1928 OS Rate (%) VERSATILE-002 VERSATILE-002 ® ® ® KEYNOTE-048(CPS≥1) KEYNOTE-048(CPS≥1) 12-month OS Rate 24-month OS Rate
Promising Survival with PDS0101 + KEYTRUDA® 81% of Subjects Remain Alive and
Continue to be Followed for Survival Data on File. 08/02/23 Data Cut Assessments were based on Investigator assessment per RECIST 1.1 OS and PFS (mITT Population) Time to PFS OS Alive
Survival Rates Demonstrate Potential Contribution of PDS0101 to Survival in
Advanced Head and Neck Cancer PDS0101 + KEYTRUDA® Shows Promising Survival Benefit Even in ICI Resistant Patients * No controlled or comparative studies have been conducted between checkpoint inhibitors and PDS0101 Data on File. 08/02/23
Data Cut Burtness B et al., Lancet. 2019;394:1915-1928 Ferris RL, et al. NEJM. 2016;375:1856-67. Bila M, et al. Frontiers in Oncology. Jan 2022;12:761428.R/M = recurrent and metastatic 12-month Overall Survival Rate ® First-line R/M
HNSCC ICI Refractory HNSCC 12-month Overall Survival Rate Progression ® ICI-Resistant HNSCC No salvage chemotherapy
Addition of PDS0101 to KEYTRUDA® Does Not Appear to Compound Toxicity * No
controlled or comparative studies have been conducted between checkpoint inhibitors and PDS0101Data on File. 08/02/23 Data CutBurtness B et al., Lancet. 2019; 394:1915-1928 Ferris RL, et al. NEJM. 2016;375:1856-67. Only 8 ICI naïve subjects
(13%) and only 1 ICI resistant subject (4%) had Grade 3 PDS0101+KEYTRUDA® TRAE Published results 13-17% grade 3-5 TRAE with approved ICI immunotherapy in the ICI naïve population No subjects had Grade 4 or 5 TRAEs PDS0101+KEYTRUDA®
Treatment Related Adverse Events (Safety Population, N=62) Safety data in over 130 patients to date across multiple Phase 1 and 2 Studies Safety data, anti-tumor responses and patient survival suggest that the Versamune® based therapies
such as PDS0101 could be ideal candidates for combination oncology treatments Preferred Term n (%) Any Combination-TRAE 49 (79.0) Grade 1 23 (37.1) Grade 2 18 (29.0) Grade 3 8 (12.9) Grade 4 0 Grade 5 0 ICI Naïve Cohort
PDS0101+KEYTRUDA® Treatment Related Adverse Events (Safety Population, N=25) Preferred Term n (%) Any Combination-TRAE 21 (84.0) Grade 1 13 (52.0) Grade 2 7 (28.0) Grade 3 1 (4.0) Grade 4 0 Grade 5 0 ICI Resistant Cohort
PDS0101 with KEYTRUDA® Well Tolerated in VERSATILE-002 to Date with Few Serious
Toxicities Serious (Grade 3–5) Treatment-Related Adverse Events (ICI Naïve Population) *No controlled or comparative studies have been conducted between checkpoint inhibitors and PDS0101 Data on File. 08/02/23 Data Cut Burtness B et al.
Lancet. 2019;394:1915-1928 ® ® ® VERSATILE-002 No Grade 4 or 5 TRAE Subjects (%) KEYNOTE-048(CPS≥1)
Data Continues to Hold Up as More Patients are Enrolled and Follow-up Time is
Extended Data Summary Table Shows Consistency in Results PDS0101 KEYNOTE-048 Comments ASCO 2023 (06/05/23) KOL event (09/27/23) Cut-off Date January 13, 2023 August 02, 2023 Patients with CPS 1-19 50% 60% 48% Aug
02 cut off has a higher percentage of patients with CPS 1-19 (lower response to KEYTRUDA®). KEYNOTE rates among subjects with CPS ≥1 unless otherwise specified. Patients with CPS ≥20 50% 40% 52% Disease Control Rate
(SD+PR+CR) 70.6% 80.8% Patients with tumor reduction 67.6% 59.6% Confirmed ORR on cut-off date 26.5% 26.9% 19% ORR steady as more patients enroll Median OS (CPS ≥1) Not yet estimable Not yet estimable 12.3
months KEYTRUDA® exposes the cancer to the immune system (improves with higher CPS score). Injection of PDS0101 activates T cells to infiltrate, weaken (disable) and, or kill the exposed cancer cells, thus providing the potential to promote
prolonged survival. 12-month OS rate (CPS ≥1) 87% 80% 50% KEYTRUDA® exposes the cancer to the immune system (improves with higher CPS score). Injection of PDS0101 activates T cells to infiltrate, weaken (disable) and, or kill the
exposed cancer cells, thus providing the potential to promote prolonged survival. 12-month OS rate (CPS 1-19) N/A 75% 44% 12-month OS rate (CPS ≥20) N/A 85% 56% 24-month OS rate (CPS ≥1) N/A 74% 29% PFS (CPS ≥1) 10.4 months 8.1
months 3.2 months PDS0101 promotes prolonged PFS even in patients with lower CPS score. PFS for CPS ≥1 remains extended despite higher percentage of patients in lower CPS score group. PFS (CPS 1-19) 5.1 months 2.2 months PFS (CPS
≥20) 11.6 months 3.4 months * No control or comparative studies have been conducted between immune checkpoint inhibitors and PDS0101 Burtness B et al. Lancet. 2019;394:1915-1928 Burtness, B. et al. J Clin Oncol. 2022;40:2321-2332.
Combination of PDS0101 & KEYTRUDA® Continues to Show Promising Safety and
Survival Outcomes VERSATILE-002 Study Shows Potential of PDS0101 to Safely Modify the Tumor Microenvironment to Promote Patient Survival The 24-month OS rate in the ICI naïve cohort is 74%; Published results of 29% in KEYNOTE-048 The
12-month OS rate in the ICI naïve cohort is 80%; Published results of 50% in KEYNOTE-048 The addition of PDS0101 to KEYTRUDA® does not appear to compound toxicity in ICI naïve patients 13% (8/62) Grade 3 and 0% Grade 4 & 5 Treatment
Related Adverse Events * No controlled or comparative studies have been conducted between checkpoint inhibitors and PDS0101 Data on File. 08/02/23 Data Cut. Burtness B, et al. Lancet. 2019;394:1915-28.
Timeline to Registrational Trial Initiation Worldwide Randomized, Controlled
Clinical Study to Be Initiated Q1 2024 PDS0101 + KEYTRUDA® in Recurrent or Metastatic HPV16-Positive HNSCC 2Q 2022 3Q 2022 1Q 2023 2Q 2023 3Q 2023 1Q 2024 FDA Fast Track designation for PDS0101 + KEYTRUDA® Successful EOP2 meeting
with FDA Initiated PDS0101 tech-transfer, scale up at selected Phase 3 clinical/commercial manufacture Completed Phase 3 clinical manufacturing of PDS0101 Obtained visibility to potential OS and PFS information for VERSATILE-002 trial
needed to finalize VERSATILE-003 trial design Completed CMC-related activities for PDS0101 Obtained feedback from EU regulatory agencies on protocol Received feedback from FDA allowing for initiation of VERSATILE-003 Initiate site
activation and related clinical, operational activities (4- to 6-month process) InitiateVERSATILE-003 Phase 3 Trial
Versamune® Based Oncology Pipeline Partnerships with World-Class Institutions
in Immuno-Oncology Reference: Data on file. PDS Biotech Funded Candidate/ Study Indication Combination PC P1 P2 P3 R Partner(s) Clinical (Lead) PDS0101 (HPV)/ VERSATILE-002 Recurrent or metastatic HPV16-positive head and neck
cancer Arm 1: ICI naïve Arm 2: ICI refractory KEYTRUDA® (standard of care) IIT Studies PDS0101 (HPV)/ IMMUNOCERV 1st-line treatment of locally advanced (IB3-IVA) cervical cancer Chemo-radiation (standard of care) PDS0101
(HPV)/ Mayo Clinic Pre-metastatic HPV-positive oropharyngeal cancer (OPSCC) Arm 1: PDS0101 monotherapy Arm 2: PDS0101 + KEYTRUDA® KEYTRUDA® (standard of care) Preclinical Candidates PDS0102(TARP) TARP-positive AML, prostate and
breast cancers TBD PDS0103 (MUC1) MUC1-positive breast, colon, lung, ovarian and other cancers TBD PDS0104(TRP2) Melanoma TBD Partner Co-Funded Fast Track Designation
VERSATILE-003 Phase 3 Study Design Global Randomized, Controlled Clinical Study
with Estimated 90–100 Sites Overall survival (OS) Primary Endpoint For the treatment of recurrent or metastatic HPV16-positive HNSCC Targeted Indication Randomization 2:1 PDS0101 +KEYTRUDA® PDS0101 + KEYTRUDA®
KEYTRUDA® KEYTRUDA® Planned Interim Analysis: OS Final Analysis:OS Enrollment Follow-up
Antibody-Drug Conjugate (ADC) IL-12 (PDS01ADC) Phase 2 Clinical Studies
PDS0101+PDS01ADC+ICI: Optimal Antitumor Response Preclinical: Increased T Cells
and T Cell Uniformity with Tumor Shrinkage NHS-IL12 + ICI PDS0101 + NHS-IL12 + ICI A) Immunohistochemistry for CD4+ and CD8+ T cells in TC-1 tumors. Combination treatment with PDS0101, NHS-IL12 (IL-12 ADC), and ICI (bintrafusp alfa)
increased CD8 and CD4 T cell infiltration into the tumor. B) PDS0101 monotherapy reduced tumor volume in the TC-1 syngeneic tumor model, and the combination of PDS0101, bintrafusp alfa and NHS-IL12 resulted in further tumor control. C) TCR
clonality significantly increased in all groups treated with PDS0101. Tumor infiltrating lymphocytes (TILs) were purified from whole tumor. DNA isolated from TILs was analyzed by Adaptive Biotechnology for TCR repertoire. Number of T-cell
clones that make up 25% of the TCR repertoire (n=3 mice per group). D) CD8+ T cell infiltration in tumor. Similar results obtained with traditional aPD-L1 ICI (unpublished data) CD4 T cells, CD8 T cells, DAPI A B C D Smalley, Rumfield
C, et al. J Immunother Cancer 2020;8:e000612. doi:10.1136/jitc-2020-000612
Phase 2 NCI-led Triple Combination: PDS01ADC + PDS0101 + ICI Advanced
HPV16-Positive Anal, Cervical, Head and Neck, Penile, Vaginal, Vulvar Cancer Patients Who Are ICI Resistant 172% grade 3 and higher adverse events reported in KEYNOTE-048 Burtness 2019 https://doi.org/10.1016/S0140-6736(19)32591-7 Goswami
2022 http://dx.doi.org/10.1136/jitc-2022-SITC2022.0695 Partner FDA Approved Standard of Care None Immunology/Immune Correlates SITC, November 2022: Greater than two-fold increase in HPV16-specific T cells in the blood of 11/14 (79% )
of the evaluated patients Induction of multifunctional killer (CD8) T cells Increases in granzyme B (associated with active killer T cells), IFN-γ, TNF-α, etc., signal a pro-inflammatory response and role in overcoming tumor immune
suppression Safety Safety results (Arms 1 & 2)1 24/50 (48%) of patients experienced grade 3 and higher adverse events 2/50 (4%) experienced grade 4 adverse events
Triple Combination: Promising Objective Response Rate (ORR) ICI Naïve
Patients Percent of Patients (%) 19% 27% 75% 1 2 3 27% 75% 1 1. Burtness B et al., Lancet. 2019; 394:1915-1928 2. VERSATILE-002 Phase 2 trial (NCT04260126), Investigator assessment (10/2023) 3. Triple combination Phase 2 trial
(NCT04287868, Investigator assessment (data on file) Note: No controlled or comparative studies have been conducted between checkpoint inhibitors and PDS0101 or PDS01ADC KEYTRUDA 1 PDS0101+KEYTRUDA 2 KEYTRUDA +Chemo 1 PDS0101+PDS01ADC+ICI
3 ® ® ® PDS0101ADC Promoted Promising ORR
Overall Survival Rates – Durable Survival with PDS0101ICI Naïve Patients OS
Rate (%) 50 55 80 25% 31 74 75 75% 29% 22% 1 1 2 3 74% 75% 1. Burtness B et al., Lancet. 2019; 394:1915-1928 2. VERSATILE-002 Phase 2 trial (NCT04260126), Investigator assessment (10/2023) 3. Triple combination Phase 2
trial (NCT04287868, Investigator assessment (11/2023) Note: No controlled or comparative studies have been conducted between checkpoint inhibitors and PDS0101 or PDS01ADC KEYTRUDA®1 KEYTRUDA®+Chemo 1 KEYTRUDA®+PDS0101
2 PDS0101+PDS01ADC+ICI 3 PDS0101-Containing Combinations Promoted Promising Survival Benefit N/A
Triple Combination: Compelling Objective Response Rate (ORR)ICI Resistant
Patients 1. Strauss J et al, Journal for ImmunoTherapy of Cancer 2020;8:e001395 doi:10.1136/jitc-2020-001395 2. Pestana et al, Oral Oncology 101 (2020) 104523 3. VERSATILE-002 Phase 2 trial (NCT04260126), Investigator assessment
(10/2023) 4. Triple combination Phase 2 trial (NCT04287868, Investigator assessment (11/2023) Note: No controlled or comparative studies have been conducted between checkpoint inhibitors and PDS0101 or PDS01ADC 10% 42% 63%* Percent of
Patients (%) 2 1 3 4 PDS0101+PDS01ADC+ICI 4 KEYTRUDA®+PDS0101 3 EGFR inhibitor+/-Chemo2 Bifunctional ICI 1 0% PDS0101ADC Promoted Promising ORR *High dose PDS01ADC
Triple Combination: 1-Year Overall Survival Rate ICI Resistant
Patients 30% 56% 72% Surviving Patients (%) 1 3 2 36% 72% 56% PDS0101+PDS01ADC+ICI 3 PDS0101+KEYTRUDA® 2 Systemic Therapies 1 1. Pestana et al, Oral Oncology 101 (2020) 104523 2. VERSATILE-002 Phase 2 trial (NCT04260126),
Investigator assessment (10/2023) 3. Triple combination Phase 2 trial (NCT04287868, Investigator assessment (11/2023) Note: No controlled or comparative studies have been conducted between checkpoint inhibitors and PDS0101 or
PDS01ADC PDS0101-Containing Combinations Promoted Promising Survival Benefit with Addition of PDS01ADC Providing Further Benefit
Combination of PDS0101, PDS01ADC and Immune Checkpoint Inhibitor (ICI) Shows
Promising Safety, ORR and Survival Outcomes Triple Combination Study Shows Potential PDS0101 and PDS01ADC to Safely Modify TME to Promote both Patient Survival and Objective Responses in HPV-Positive Cancers The 36-month OS rate in the ICI
naïve cohort is 75%; Published results of <30% 36-month with FDA approved therapies The confirmed objective response rate (ORR) in the ICI naïve cohort is 75%; Published results of <40% with FDA approved therapies The 12-month OS rate
in the ICI resistant cohort is 72%; Published results of <40% with combinations of various FDA-approved systemic therapies The Triple Combination appears to be reasonably well tolerated in ICI naïve and ICI resistant patients 48%
(24/50) Grade 3 and 4% (2/50) Grade 4 Treatment-Related Adverse Events * No controlled or comparative studies have been conducted between checkpoint inhibitors and PDS0101 or PDS01ADC Data on File. 08/02/23 Data Cut. Burtness B, et al.
Lancet. 2019;394:1915-28.
IL-12 ADC Cytokine TherapyPDS01ADC + Docetaxel Phase 2 Clinical Study: PDS01ADC
+ Docetaxel in Advanced Prostate Cancer
PDS01ADC (IL-12 ADC) + Docetaxel: Optimal Tumor ControlPreclinical studies show
PDS01ADC accumulation in tumor with efficacy Cancer Immunology, Immunotherapy (2023) 72:2783–2797 Colon cancer (MC38) average tumor volumes of animals treated with docetaxel (red line; n = 11), PDS01ADC (blue line; n = 11), rIL-12 (grey
line; n = 11), docetaxel + PDS01ADC (purple line; n = 12), docetaxel + recombinant IL-12 (rIL- 12) (green line; n = 11) and untreated controls (black line; n = 12).Doc = docetaxel. huIgG = human IgG. *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001 TME – Tumor microenvironment Docetaxel + PDS01ADC Docetaxel + rIL-12 Docetaxel rIL-12 PDS01ADC MC38 Colon Cancer Tumor Growth No Treatment
PDS01ADC+Docetaxel: Well Tolerated at All Tested Dose LevelsCastration-Sensitive
and Castration-Resistant Prostate Cancer Patients Adverse Event 6.0mcg/kg NHS-IL12 N=6 12.0mcg/kg NHS-IL12 N=6 16.8mcg/kg NHS-IL12 N=6 Grade 2 Grade 3 Grade 4 Grade 2 Grade 3 Grade 4 Grade 2 Grade 3 Grade
4 Fatigue 33% 0% 0% 17% 17% 0% 60% 0% 0% Anemia 0% 0% 0% 33% 17% 0% 0% 20% 0% Lymphopenia 0% 0% 0% 67% 0% 0% 0% 0% 0% Diarrhea 0% 0% 0% 17% 0% 0% 20% 20% 0% Neutropenia 0% 17% 0% 0% 0% 17% 20% 0% 0% Leukopenia 17% 0% 0% 0% 17% 0% 20% 0% 0% Febrile
Neutropenia 0% 0% 0% 0% 0% 0% 0% 20% 0% Madan et al, Cytokines 2023
PDS01ADC + Docetaxel: 61% Average PSA DeclineImmune Responses and PSA Decline
Seen at All Dose Levels -4 -22 -46 -62 -75 -86 -14 -27 -40 8.0mcg/kg 12.0mcg/kg 16.8mcg/kg CRPC CSPC CRPC = castration-resistant prostate cancer; CSPC = castration-sensitive prostate cancer; PSA = prostate-specific
antigen Madan et al, Cytokines 2023
Antibody-Drug Conjugate (PDS01ADC) Pipeline Reference: Data on
file. Candidate/ Study Indication Combination PC P1 P2 P3 R Partner(s) IIT Studies PDS01ADC/ NCI-led Triple Combination HPV-positive anal, cervical, head and neck, penile, vaginal, vulvar cancers Arm 1: ICI naive Arm 2: ICI
resistant PDS0101 & ICI IIT Studies PDS01ADC Advanced Kaposi Sarcoma Monotherapy PDS01ADC Metastatic castration-sensitive and castration-resistant prostate cancer Docetaxel PDS01ADC Localized high and intermediate risk prostate
cancer Radiation Therapy PDS01ADC ICI refractory HPV-related, colon and small-bowel cancer HDAC Inhibitor Partner Co-Funded
4Q23 1Q24 2Q24 3Q24 PDS0101 Submit protocol to FDA for triple
combination in HNSCC Update on ICI naïve/resistant data in HNSCC – KOL Event (VERSATILE-002) Updated OS data from PDS0101-PDS01ADC based triple combination in HPV-Positive Cancer Immune response data (VERSATILE-002) (ESMO
2023) Initiate registrational trial (HPV16-Positive HNSCC) Anticipate updated data (IMMUNOCERV) (ASTRO 2023) Anticipate preliminary efficacy data (Mayo Clinic) Final data VERSATILE-002 PDS01ADC Interim safety and immune data
(PDS01ADC + docetaxel) (Cytokines 2023) PDS0103 Estimated IND filing in MUC1-related cancers PDS0202 Feedback from NIAID on path forward for universal flu Projected Milestones Through 3Q24 Investigator-initiated trials and data
read-outs are outside the control of PDS Biotech.
4Q23 1Q24 2Q24 3Q24 PDS0101 Submit IND with FDA for Triple Combination in
HNSCC Update on ICI naïve/resistant data in HNSCC – KOL Event (VERSATILE-002) Updated OS data from PDS0101-PDS01ADC based triple combination in HPV-Positive Cancer Immune response data (VERSATILE-002) (ESMO 2023) Initiate registrational
trial (HPV16-Positive HNSCC) Anticipate updated data (IMMUNOCERV) (ASTRO 2023) Anticipate preliminary efficacy data (Mayo Clinic) Final data VERSATILE-002 PDS01ADC Interim safety and immune data (PDS01ADC + docetaxel) (Cytokines
2023) PDS0103 Estimated IND filing in MUC1-related cancers PDS0202 Feedback from NIAID on path forward for universal flu Projected Milestones Through 3Q24 Investigator-initiated trials and data read-outs are outside the control of PDS
Biotech.
Infectimune® Infectious Disease Platform
License agreement with University of Georgia for proprietary computer-designed
influenza antigens Top-line preclinical data announced; effective delivery of flu proteins activate the critical immune signals necessary to generate neutralizing antibody responses to all flu strains tested in animals Preclinical data
presented at the Ninth ESWI Influenza Conference and 41st Annual American Society for Virology Meeting Universal Flu Market Opportunity in 2021 PDS0202: Universal Influenza Vaccine with Potential to Revolutionize Protection Against
Influenza Reference: Ross T. and Woodward J. et al. evaluation of the PDS0202 (Infectimune® + COBRA) Universal flu formulation. Universal Influenza Vaccines $7 Billion
PDS0202 Promotes Induction of Antibodies that Neutralize a Broad Range of
Influenza Viral Strains in Ferret Studies Proprietary Computationally Designed Influenza Protein Studies in Ferrets – Model Viewed as Gold Standard in Preclinical Influenza Research
PDS0202 Promotes Induction of Antibodies and T Cells that Prevent Viral
Replication in Lungs of Ferrets Proprietary Computationally Designed Influenza Protein
PDS0101 to enter Phase 3 registrational trial in Q1 2024 to treat recurrent or
metastatic, HPV16-positive head and neck squamous cell cancer (HNSCC) Fast Track Designation PDS0101 addresses large and growing market with significant unmet need Transformational data generated with PDS0101 and PDS01ADC in multiple Phase
2 clinical studies Financial: Cash as of September 30, 2023 - $54.3M - Adequate cash runway into Q3 2024 with initiation of a registrational trial in 2024 Executive Summary: Positioned for Market Leadership Company Overview T cell
activating platforms and antibody conjugated immunocytokine platform to develop safer, more effective and longer-lasting cancer immunotherapies 1 2 3 4
Thank You
Appendix
FDA Requires OS as Primary Endpoint PFS and ORR will not support a BLA
approval From FDA’s Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics White Paper1: “In the 1970’s, the FDA usually approved cancer drugs based on objective response rate (ORR), determined by tumor assessments from
radiological tests or physical examinations. In the early 1980s, after discussion with the Oncologic Drugs Advisory Committee (ODAC), the FDA determined that cancer drug approval should be based on more direct evidence of clinical benefit,
such as improvement in survival, improvement in a patient’s quality of life, improved physical functioning, or improved tumor-related symptoms. These benefits may not always be predicted by, or correlate with, ORR.” FDA Quote from Minutes of
PDS Biotech End of Phase 2 Meeting with the FDA: “If Study PDS0101-HNC-301 is to be conducted with registrational intent, overall survival (OS) should be the primary endpoint, particularly given that recent recently approved immunotherapies
for HNSCC have demonstrated in median OS but not always in PFS.” 1https://www.fda.gov/media/71195/download
VERSATILE-002 ICI Naïve Key Demographics and Treatment Exposure Majority of
Patients Are CPS 1-19 Demographic ITT Population (N=55) mITT Population (N=52) Age, Median (Min, Max) 64.0 (46, 83) 64.0 (46, 83) Sex, n (%) Male Female 51 (92.7) 4 (7.3) 48 (92.3) 4 (7.7) Race, n (%) American Indian or
Alaska Native Asian Black or African American Pacific Islander White Other 0 1 (1.8) 1 (1.8) 0 52 (94.5) 1 (1.8) 0 1 (1.9) 1 (1.9) 0 49 (94.2) 1 (1.9) ECOG, n (%) 0 1 32 (58.2) 23 (41.8) 29 (55.8) 23
(44.2) CPS, n (%)* <1 1–19 ≥20 0 33 (60.0) 22 (40.0) 0 31 (59.6) 21 (40.4) Data on File. 08/02/23 Data Cut. Treatment Exposure(ITT Population) Median number of PDS0101 doses: 4 (range 1–5) 72.7% received ≥4 doses25.5%
received 5 doses (5th dose is 6 months after dose 4) Median number of KEYTRUDA® doses: 7 (range 1–33) 32.7% received ≥10 doses
Expanding Evidence of Consistent and Durable PDS0101 Clinical Results Across
Multiple Phase 2 Trial Indications PDS0101 is an HPV16-targeted immunotherapy PDS0101 is providing strong proof of concept data for the Versamune® technology platform Efficacy data in >90 patients to date Strong agreement between
preclinical and clinical results Versamune® mechanism of action shows clear translation between preclinical and human results Anti-tumor responses and biomarker data show strong correlation across all types of HPV-positive cancer and at all
stages of the disease Safety data in approximately 130 patients to date Safety data, anti-tumor responses and patient survival suggest that the Versamune® based therapies such as PDS0101 could be ideal candidates for combination oncology
treatments
HNSCC is a Devastating Group of Cancers Reference: Noseyaba et al. 2018.
Cancer. Suicide Risk Among Cancer Survivors: Head and Neck Versus Other Cancers https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01688-9 https://www.cdc.gov/cancer/hpv/basic_info/hpv_oropharyngeal.html *Human
Papillomavirus Oral and PharyngealCancers Genotype of *HPV-Positive Oral and Pharyngeal Cancer Paranasalsinuses Nasopharynx Oropharynx Hypopharynx Larynx Pharynx Tongue Salivaryglands OralCavity NasalCavity
Antibody Drug Conjugate IL-12: PDS0301 Targets Tumors and Enhances T Cell
Infiltration and Proliferation in the Tumor Tumor Site Injection Site Non-Immunogenic (Cold Tumor) Immunogenic (Hot Tumor) Tumor Site PDS0301 travels direct to tumor Increased tumor inflammation from PDS0301 PDS0301 increases T cell
infiltration and expansion in tumor CD8 T cells kill tumor cells 1 2 3 4
PDS0101: A Novel Investigational HPV-Targeted Immunotherapy PDS0101 is given
by subcutaneous injection and stimulates a potent targeted T cell attack against HPV-positive cancers Interim VERSATILE-002 data suggests PDS0101 generates clinically effective immune responses The combination of PDS0101 with KEYTRUDA® has
demonstrated a favorable safety profile to date PDS0101 with KEYTRUDA® demonstrates significant disease control by shrinking tumors, delaying disease progression and prolonging survival
PDS01ADC (NHS-IL12)+Docetaxel: Optimal Tumor ControlPreclinical Studies Show
Necrosis and IL-12 Accumulation in TME (A) Quantification of percent necrosis of MC38 tumor-bearing animals that were untreated (black symbols; n = 3) or received docetaxel monotherapy (red symbols; n = 2), NHS-IL-12 monotherapy (blue
symbols; n = 3) or docetaxel + NHS-IL-12 combination therapy (purple symbols; n = 2). Cancer Immunology, Immunotherapy (2023) 72:2783–2797 A B C (C) MC38 average tumor volumes of animals treated with docetaxel (red line; n = 11),
NHS-IL-12 (blue line; n = 11), rIL-12 (grey line; n = 11), docetaxel + NHS-IL-12 (purple line; n = 12), docetaxel + rIL- 12 (green line; n = 11) and untreated controls (black line; n = 12).Doc = docetaxel. huIgG = human IgG. *p < 0.05, **p
< 0.01, ***p < 0.001, ****p < 0.0001 (B) Enumeration of NHS-IL-12 via ELISA found intratumorally in untreated animals (n = 5) and animals receiving docetaxel (n = 5), NHS-IL-12 (n = 6), and docetaxel + NHSIL- 12 combination therapy
(n = 6). TME – Tumor microenvironment